Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
2011 2
2012 1
2016 1
2017 2
2018 2
2019 1
2020 3
2021 9
2022 9
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H, Sweep MWD, Gorris MAJ, Hoentjen F, Boers-Sonderen MJ, van der Post RS, van den Heuvel MM, Piet B, Boleij A, Bloemendal HJ, de Vries IJM. Westdorp H, et al. Among authors: piet b. Front Immunol. 2021 Oct 29;12:768957. doi: 10.3389/fimmu.2021.768957. eCollection 2021. Front Immunol. 2021. PMID: 34777387 Free PMC article. Review.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Clinical Trial.
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.
van der Woude LL, Gorris MAJ, Wortel IMN, Creemers JHA, Verrijp K, Monkhorst K, Grünberg K, van den Heuvel MM, Textor J, Figdor CG, Piet B, Theelen WSME, de Vries IJM. van der Woude LL, et al. Among authors: piet b. J Immunother Cancer. 2022 Oct;10(10):e005248. doi: 10.1136/jitc-2022-005248. J Immunother Cancer. 2022. PMID: 36252995 Free PMC article.
A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies.
Scott JI, Mendive-Tapia L, Gordon D, Barth ND, Thompson EJ, Cheng Z, Taggart D, Kitamura T, Bravo-Blas A, Roberts EW, Juarez-Jimenez J, Michel J, Piet B, de Vries IJ, Verdoes M, Dawson J, Carragher NO, Connor RAO, Akram AR, Frame M, Serrels A, Vendrell M. Scott JI, et al. Among authors: piet b. Nat Commun. 2022 May 2;13(1):2366. doi: 10.1038/s41467-022-29691-w. Nat Commun. 2022. PMID: 35501326 Free PMC article.
Recent Advances and Future Perspective of DC-Based Therapy in NSCLC.
van der Hoorn IAE, Flórez-Grau G, van den Heuvel MM, de Vries IJM, Piet B. van der Hoorn IAE, et al. Among authors: piet b. Front Immunol. 2021 Jun 28;12:704776. doi: 10.3389/fimmu.2021.704776. eCollection 2021. Front Immunol. 2021. PMID: 34262573 Free PMC article. Review.
Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.
van Genugten EAJ, Weijers JAM, Heskamp S, Kneilling M, van den Heuvel MM, Piet B, Bussink J, Hendriks LEL, Aarntzen EHJG. van Genugten EAJ, et al. Among authors: piet b. Front Oncol. 2022 Jan 7;11:786089. doi: 10.3389/fonc.2021.786089. eCollection 2021. Front Oncol. 2022. PMID: 35070990 Free PMC article. Review.
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, Croes S, van Geel RMJM, Jansman FGA, Boshuizen RC, Franssen EJF, Smit AAJ, Dumoulin DW, Oude Munnink TH, Smit EF, Derijks HJ, van der Leest CH, Hendrikx JJMA, Moes DJAR, de Rouw N. Ter Heine R, et al. Among authors: piet b. Target Oncol. 2023 May;18(3):441-450. doi: 10.1007/s11523-023-00958-6. Epub 2023 Apr 21. Target Oncol. 2023. PMID: 37081309 Free PMC article.
Hyperhydration with cisplatin does not influence pemetrexed exposure.
de Rouw N, Derijks HJ, Hilbrands LB, Boosman RJ, Piet B, Koolen SLW, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Aerts JGJV, Croes S, Mathijssen RHJ, Huitema ADR, Burger DM, Biesma B, Ter Heine R. de Rouw N, et al. Among authors: piet b. Br J Clin Pharmacol. 2022 Feb;88(2):871-876. doi: 10.1111/bcp.15031. Epub 2021 Aug 26. Br J Clin Pharmacol. 2022. PMID: 34374116 Free PMC article.
32 results